icad (ICAD) Retained Earnings : $-272.91 Mil (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is icad Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. icad's retained earnings for the quarter that ended in Mar. 2024 was $-272.91 Mil.

icad's quarterly retained earnings increased from Sep. 2023 ($-273.74 Mil) to Dec. 2023 ($-271.68 Mil) but then declined from Dec. 2023 ($-271.68 Mil) to Mar. 2024 ($-272.91 Mil).

icad's annual retained earnings declined from Dec. 2021 ($-253.18 Mil) to Dec. 2022 ($-266.84 Mil) and declined from Dec. 2022 ($-266.84 Mil) to Dec. 2023 ($-271.68 Mil).

icad Retained Earnings Historical Data

The historical data trend for icad's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Retained Earnings Chart

icad Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-224.33

-241.94

-253.18

-266.84

-271.68

icad Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-270.61	-272.36	-273.74	-271.68	-272.91

icad Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

icad (NAS:ICAD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

icad (ICAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062

Website

https://www.icadmed.com

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Executives

Eric Lonnqvist	officer: See Remarks	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea	officer: See Remarks	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go	officer: Sr. VP of R&D	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno	officer: See Remarks	C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine	director	82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton	director	C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood	director	845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein	director	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter	officer: See Remarks	C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens	officer: Executive VP of Marketing	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado	officer: Interim Chief FinancialOfficer	98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel	director	15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard	director	C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831